Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26849975 | 1.00 | USP2 (0.56) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL2740925 | 0.96 | MEN1 (0.54) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL861278 | 0.92 | USP2 (0.64) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL24359193 | 0.90 | HPGD (0.50) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL29102574 | 0.90 | MEN1 (0.49) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL28133562 | 0.90 | USP2 (0.62) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL27893273 | 0.90 | USP2 (0.62) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| Methyl Alcohol SCHEMBL27463839 | 0.90 | USP2 (0.62) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| Iodide SCHEMBL15174787 | 0.90 | USP2 (0.62) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL16612394 | 0.90 | USP2 (0.62) | USP2SMN1; SMN2HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296762-B2 | Complexing agents and corresponding lanthanide complexes | CISBIO BIOASSAYS (FR) | 2016-03-29 | — | — | US | disclosed |
| US-20140336373-A1 | NOVEL COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES | CISBIO BIOASSAYS (FR) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336373-A1 | NOVEL COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES | RCC1, RCC2, C1R | USP2 4328/4885SMN1; SMN2 3739/4885HPGD 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.